Lonial Sagar
Known title: DirectorCIK: 0001816609
Associated companies
Transaction History
| TGTX | ▼ Sell | Open Market | 20,852 | $672K | 9/11/2025 | View on chart |
| TGTX | ▲ Buy | Grant | 14,718 | $0 | 6/12/2025 | View on chart |
| TGTX | ▼ Sell | Open Market | 5,000 | $152K | 11/11/2024 | View on chart |
| TGTX | ▼ Sell | Open Market | 16,348 | $276K | 6/20/2024 | View on chart |
| TGTX | ▲ Buy | Grant | 22,250 | $0 | 6/19/2024 | View on chart |
| TGTX | ▼ Sell | Open Market | 9,585 | $157K | 6/17/2024 | View on chart |
| TGTX | ▼ Sell | Open Market | 5,000 | $80K | 3/13/2024 | View on chart |
| TGTX | ▲ Buy | Grant | 20,000 | $0 | 9/28/2023 | View on chart |
| TGTX | ▼ Sell | Open Market | 34,854 | $815K | 6/23/2023 | View on chart |
| TGTX | ▲ Buy | Grant | 43,732 | $0 | 7/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
TGTX Highlighted as Affordable Biotech Growth Play
ChartMill recently featured TG Therapeutics as an affordable growth option within the biotech sector. This analysis suggests the stock may be viewed as undervalued relative to its potential, despite trading near its 52-week low. The mention adds a positive fundamental perspective to the current technical setup.
TGTX Highlighted as Affordable Biotech Growth Play. ChartMill recently featured TG Therapeutics as an affordable growth option within the biotech sector. This analysis suggests the stock may be viewed as undervalued relative to its potential, despite trading near its 52-week low. The mention adds a positive fundamental perspective to the current technical setup.